SPY337.76+0.32 0.09%
DIA279.46-0.58 -0.21%
IXIC11,101.67+89.43 0.81%

Sangamo Therapeutics shares are trading higher after the company announced a global collaboration with Novartis to develop genomic medicines for autism and other neurodevelopmental disorders. Sangamo will receive a $75 million upfront payment and is eligible to receive up to $720 million in potential milestones.

Benzinga · -